U.S. FDA Grants 510(k) Clearance for Spectral’s DIMI

Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities U.S. skilled nursing facilities market represents an estimated US$2 billion market annually TORONTO, Canada – August 31, 2020 – Spectral Medical Inc. (“Spectral” or the...
Read More

Spectral Medical Provides Corporate Update

Early Tigris trial observations in-line with Euphrates post-hoc results Investigator-driven studies show endotoxin levels significantly elevated in most patients with COVID-induced septic shock Q4 2020 EAA multi-country European launch DIMI traditional FDA 510(k)...
Read More

Spectral Medical Inc. Files Base Shelf Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | July 6, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.